Biotechnology
XtalPi AI Enables Seven-Month PCC Nomination for Viva-Thera's MPER-Targeting HIV-1 Program
* Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and cure, supported by XtalPi's platform capabilities. * Viva-Thera combines its first atomic-resolution MPER-TMD-CT structure with XtalPi's AI and automation platform to advance a small-molecule PCC. ...
2026-09-23 01:36
960
Tsingke Enables High-Throughput Validation of AI-Designed Proteins and Antibodies
BEIJING, Sept. 22, 2026 /PRNewswire/ -- Tsingke today announced an integrated high-throughput validation workflow designed to help researchers experimentally evaluate large libraries of AI-designed proteins and antibodies. Combining gene synthesis, parallel expression, high-throughput screening, ...
2026-09-22 22:22
824
BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset
SUZHOU, China, Sept. 22, 2026 /PRNewswire/ -- Boomray Pharmaceuticals Co., Ltd. ("BoomRay"), a clinical-stage biotechnology company pioneering innovative radioligand therapies (RLTs) for precision oncology diagnostics and therapeutics, today announced that it has entered into an exclusive global ...
2026-09-22 12:00
2052
Bestzyme Launches World's First Dedicated, Automated Smart Production Line for Sweet Proteins in Jinan
JINAN, China, Sept. 21, 2026 /PRNewswire/ -- Bestzyme, a synthetic biology company under GenScript Biotech, today announced the completion of the world's first dedicated, automated smart production line for sweet proteins at its Jinan facility. This milestone marks the first full-chain integratio...
2026-09-22 10:30
2220
Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026
HONG KONG, Sept. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")announced that nearly 30 clinical studies of its globally first-in-class bispecific antibodies will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place October 23–27 ...
2026-09-22 07:46
2171
The Next Chapter of B7-H3: From Systemic Disease to the Brain
Early Data for T-MAXIMUM's B7-H3 Allogeneic CAR-T in Brain Metastases Presented at WCLC 2026 BEIJING, Sept. 21, 2026 /PRNewswire/ -- As B7-H3 ADCs reshape the second-line treatment landscape for small cell lung cancer at WCLC, a more specific question comes into focus: systemic disease now has n...
2026-09-21 19:50
1310
WuXi XDC Celebrates GMP Release of Singapore Site, Ushering in a New Era of Global Expansion
SINGAPORE, Sept. 21, 2026 /PRNewswire/ --WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today held a grand GMP release ceremony for its Singapore manufacturing sit...
2026-09-21 17:50
2694
Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia
SINGAPORE, Sept. 20, 2026 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST)today announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ: INCY), to commercialise, distribute, and register ruxolitini...
2026-09-21 04:00
2344
Accro Bioscience Announces First Patient Dosed in Phase IIb Study of AC-101 in Moderate-to-Severe Ulcerative Colitis
NEW YORK and SUZHOU, China, Sept. 20, 2026 /PRNewswire/ -- Accro Bioscience Inc. (Accro Bio), a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune mediated diseases, today announced the dosing of their first patient in the Phase IIb clinical trial of ...
2026-09-20 18:00
3013
NAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMed
* ImpriMed combines ex vivo functional testing with multimodal AI to support personalized cancer treatment decisions and drug development * The investment is part of ImpriMed's $10 million Series A2 bridge round as the company advances U.S. commercialization and expands into Asia * NAVER D2S...
2026-09-18 23:00
3487
Dr. Alison Armour agrees to become Chief Medical Officer of Alpha Fusion, as Company Advances Integration of At-211 Businesses with Curadh MTR
— Combining Both Companies' Astatine At-211 Assets, Development Capabilities, and Supply Chains to Create a Global Targeted Alpha Therapy Company — TOKYO, Sept. 17, 2026 /PRNewswire/ -- Alpha Fusion Inc. ("Alpha Fusion"), a clinical-stage company with an advanced At-211 drug platform, and Curadh ...
2026-09-17 19:00
2479
WuXi XDC Out-Licenses WuXiTecan-2 Payload-Linker Technology Platform to Ona Therapeutics to Advance Novel ADC Research and Development
SHANGHAI, Sept. 17, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced an out-licensing collab...
2026-09-17 16:09
2713
111, Inc. Announces Second Quarter 2026 Unaudited Financial Results
* Transition from An Asset-Heavy Business Model to An Asset-Light Business Model * Ongoing Investment and Adoption of AI Agents Making Workforce Streamlining Possible * Net Revenue of Promotional Products (1) Increased by 121% and Gross Profit Rose by 120% Year-over-Year * Total Marketpla...
2026-09-17 15:00
6801
Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate
HONG KONG, Sept. 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that AK158D1, its investigational next-generation bispecific antibody-drug conjugate (ADC) targeting EGFR and TROP2, has secured Phase I clinical trial clearance from the Center for Drug Evaluatio...
2026-09-17 14:34
1937
Nona Biosciences Successfully Develops World's First Language Model Trained on Fully Human Heavy-Chain-Only Antibodies
CAMBRIDGE, Mass., Sept. 16, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, today announced the development of HCAbLM, the world's first language model specifically trained on ful...
2026-09-16 18:01
2093
WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership
SHANGHAI, Sept. 16, 2026 /PRNewswire/ -- Forbes China recently released the 2026 Forbes China ESG 50 list. WuXi Biologics was named to the list for its outstanding performance in sustainable development, Green CRDMO solutions and ESG digital innovation, and was highlighted by Forbes China as one ...
2026-09-16 16:57
2540
Ractigen Therapeutics to Present First-in-Human RNA Activation Data in Duchenne Muscular Dystrophy as a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle Society
* Late-Breaking selection at the 31st Annual World Muscle Society Congress — a designation reserved for findings the program committee determines to be of immediate importance to the field * Presentation expected to provide the first clinical evidence that a small activating RNA (saRNA) can u...
2026-09-15 22:19
3274
Xylo Bio Achieves Clinical-Stage Milestone with XYL-1001, a Highly Selective Neuroplastogen Targeting Major Depressive Disorder
BOSTON, Sept. 15, 2026 /PRNewswire/ -- Xylo Bio, a clinical-stage biotechnology company developing novel neurotherapeutics for psychiatric and neurological disorders, today announced the first participants dosed in its Phase 1 clinical study of XYL-1001, a novel, selective 5-HT2A agonist being de...
2026-09-15 18:00
1851
Oral Presentation: Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 at WCLC 2026
HONG KONG, Sept. 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303) at the 2026 World Conference on Lung Cancer (WCLC), organ...
2026-09-15 14:14
2325
REJURAN® COSMETICS Brings K-Beauty to LAFC Korean Heritage Night as Proud Skincare Partner
Korea's original PDRN brand connected with Los Angeles football fans through product sampling and creator experiences LOS ANGELES, Sept. 14, 2026 /PRNewswire/ -- REJURAN® COSMETICS, Korea's original PDRN brand from PharmaResearch, joined LAFC's Korean Heritage Night on Wednesday, Sept. 9, as a P...
2026-09-14 23:07
2540
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 277 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 277 media titles]
2026-10-06 05:28Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 271 media titles]
2026-10-01 10:00
Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines
[Picked up by 263 media titles]
2026-10-02 16:27
Southeast Asia's China travel map is widening, Traveloka platform data shows
[Picked up by 262 media titles]
2026-10-05 11:51Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
24046